Drugs targeting the immune system have been widely exploited in the treatment of inflammatory, allergic and autoimmune disorders during the second half of the 20th century. The recent advances in immunopharmacological research made available new classes of clinically relevant drugs, comprising protein kinase inhibitors and biologics, such as monoclonal antibodies that selectively modulate the immune responses. ImmuPhar is the Immunopharmacology Section of IUPHAR, providing a unique international expert-lead platform aiming to dissect and promote the growing understanding of immune system as well as to challenge the identification and validation of drug targets and lead candidates for the treatment of many forms of debilitating immunological diseases. In this symposium I will outline the current movement on immunopharmacology in Japan as well as the activity of ImmuPhar, and discuss future perspectives in this trend.